 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | bilirubin nanoparticle (OPTA-INFLA oral) / Bilix
Journal: Synthetic Bilirubin-Based Nanomedicine Protects Against Renal Ischemia/Reperfusion Injury Through Antioxidant and Immune-Modulating Activity. (Pubmed Central) - Mar 17, 2025
In conclusion, BX-001N, the first Good Manufacturing Practice-grade synthetic bilirubin-based nanomedicine attenuates acute renal injury and chronic fibrosis by suppressing ROS generation and inflammation after IRI. It shows adequate safety profiles and holds promise as a new therapy for renal IRI.
- || bilirubin nanoparticle (OPTA-INFLA oral) / Bilix
PK/PD data, Preclinical, Journal: Investigation of pharmacokinetic properties of a PEGylated bilirubin nanoparticle in male Sprague-Dawley rats using liquid chromatography-quadrupole time-of-flight mass spectrometry. (Pubmed Central) - Nov 17, 2023
and a PEGylated bilirubin 3? nanoparticle (BX-001N, Brixelle